GlobeNewswire Inc | Oct 14, 2021 07:00AM EDT

October 14, 2021

CALGARY, Alberta, Oct. 14, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the Company) (CSE: XRX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, announces its participation in the LD Micro Main Event, being held October 12 through 14, 2021.

Dr. Allen Davidoff stated, LD Micro is a premier MicroCap investor conference, we are pleased to be invited to present to their investor groups that include institutions, family offices and life science analysts.

Chris Lahiji, Founder of LD Micro, added, "We are honored to be back in person with some of the finest companies and investors in the small-cap world. After nearly two years, I for one, cannot wait to reconnect both as an executive, event coordinator, and investor."

Attendee Registration Link:

XORTX Therapeutics - LD Micro Main Event: 10 am ET October 14, 2021

A replay of the presentation will be posted on the investor relations section of the companys website at https://www.xortx.com/investors/.

About LD Micro

LD Micro aims to be the most critical resource in the micro-cap world. Whether it is the index, comprehensive data, or hosting the most significant events annually, LD's sole mission is to be an invaluable tool for all those interested in finding the next generation of great companies.

About XORTX Therapeutics Inc.

XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX Therapeutics is available at www.xortx.com.

For further information, please contact:

Allen Davidoff, CEO Nick Rigopulos, Director of Communicationsadavidoff@xortx.com or +1 403 455 nick@alpineequityadv.comor +1 617 9017727 0785

The CSE and Nasdaq have neither approved nor disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.